140 related articles for article (PubMed ID: 24689045)
1. Flow cytometry assessment of in vitro generated CD138+ human plasma cells.
Itoua Maïga R; Lemieux J; Roy A; Simard C; Néron S
Biomed Res Int; 2014; 2014():536482. PubMed ID: 24689045
[TBL] [Abstract][Full Text] [Related]
2. Human CD38hiCD138⁺ plasma cells can be generated in vitro from CD40-activated switched-memory B lymphocytes.
Maïga RI; Bonnaure G; Rochette JT; Néron S
J Immunol Res; 2014; 2014():635108. PubMed ID: 25759831
[TBL] [Abstract][Full Text] [Related]
3. Impact of CD138 Magnetic Bead-based Positive Selection on Bone Marrow Plasma Cell Surface Markers.
Bansal R; Kimlinger T; Gyotoku KA; Smith M; Rajkumar V; Kumar S
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e48-e51. PubMed ID: 32873534
[TBL] [Abstract][Full Text] [Related]
4. CD138+ carcinocythemia mimicking plasma cell leukemia by flow cytometry.
Barksdale B; Leith CP
Blood; 2020 Oct; 136(14):1698. PubMed ID: 33002126
[No Abstract] [Full Text] [Related]
5. MIST1-a novel marker of plasmacytic differentiation.
Yeung CC; Mills JC; Hassan A; Kreisel FH; Nguyen TT; Frater JL
Appl Immunohistochem Mol Morphol; 2012 Dec; 20(6):561-5. PubMed ID: 22495370
[TBL] [Abstract][Full Text] [Related]
6. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells.
Caraux A; Klein B; Paiva B; Bret C; Schmitz A; Fuhler GM; Bos NA; Johnsen HE; Orfao A; Perez-Andres M;
Haematologica; 2010 Jun; 95(6):1016-20. PubMed ID: 20081059
[TBL] [Abstract][Full Text] [Related]
7. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
[TBL] [Abstract][Full Text] [Related]
8. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients.
Hosen N; Matsuoka Y; Kishida S; Nakata J; Mizutani Y; Hasegawa K; Mugitani A; Ichihara H; Aoyama Y; Nishida S; Tsuboi A; Fujiki F; Tatsumi N; Nakajima H; Hino M; Kimura T; Yata K; Abe M; Oka Y; Oji Y; Kumanogoh A; Sugiyama H
Leukemia; 2012 Sep; 26(9):2135-41. PubMed ID: 22430638
[TBL] [Abstract][Full Text] [Related]
9. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
[TBL] [Abstract][Full Text] [Related]
10. Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells.
Gattei V; Godeas C; Degan M; Rossi FM; Aldinucci D; Pinto A
Br J Haematol; 1999 Jan; 104(1):152-62. PubMed ID: 10027728
[TBL] [Abstract][Full Text] [Related]
11. Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device.
Qasaimeh MA; Wu YC; Bose S; Menachery A; Talluri S; Gonzalez G; Fulciniti M; Karp JM; Prabhala RH; Karnik R
Sci Rep; 2017 Apr; 7():45681. PubMed ID: 28374831
[TBL] [Abstract][Full Text] [Related]
12. Reversible expression of CD138 on mature follicular B cells is downregulated by IL-4.
Lee JG; Moon H; Park C; Shin SH; Kang K; Kim TJ
Immunol Lett; 2013; 156(1-2):38-45. PubMed ID: 24029663
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies.
Tembhare PR; Ghogale S; Tauro W; Badrinath Y; Deshpande N; Kedia S; Cherian K; Patkar NV; Chatterjee G; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 May; 94(3):509-519. PubMed ID: 29316178
[TBL] [Abstract][Full Text] [Related]
14. Protocol for improved resolution of plasma cell subpopulations by flow cytometry.
Wilmore JR; Jones DD; Allman D
Eur J Immunol; 2017 Aug; 47(8):1386-1388. PubMed ID: 28654161
[TBL] [Abstract][Full Text] [Related]
15. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
16. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.
Al-Quran SZ; Yang L; Magill JM; Braylan RC; Douglas-Nikitin VK
Hum Pathol; 2007 Dec; 38(12):1779-87. PubMed ID: 17714757
[TBL] [Abstract][Full Text] [Related]
17. A new staining protocol for detection of murine antibody-secreting plasma cell subsets by flow cytometry.
Pracht K; Meinzinger J; Daum P; Schulz SR; Reimer D; Hauke M; Roth E; Mielenz D; Berek C; Côrte-Real J; Jäck HM; Schuh W
Eur J Immunol; 2017 Aug; 47(8):1389-1392. PubMed ID: 28608550
[TBL] [Abstract][Full Text] [Related]
18. A counting strategy for estimating plasma cell number in CD138-stained bone marrow core biopsy sections.
Smith FB; Elnawawi A
Ann Clin Lab Sci; 2008; 38(2):138-42. PubMed ID: 18469359
[TBL] [Abstract][Full Text] [Related]
19. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms.
O'Connell FP; Pinkus JL; Pinkus GS
Am J Clin Pathol; 2004 Feb; 121(2):254-63. PubMed ID: 14983940
[TBL] [Abstract][Full Text] [Related]
20. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens.
Costes V; Magen V; Legouffe E; Durand L; Baldet P; Rossi JF; Klein B; Brochier J
Hum Pathol; 1999 Dec; 30(12):1405-11. PubMed ID: 10667416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
